BP
KRTX

Ballentine Partners’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Ballentine Partners’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,403
Closed -$304K – 655
2023
Q2 		$304K Sell
1,403
-768
-35% -$165K 0.01% 445
2023
Q1 		$394K Buy
2,171
+528
+32% +$101K 0.01% 352
2022
Q4 		$323K Buy
1,643
+483
+42% +$104K 0.01% 362
2022
Q3 		$261K Buy
+1,160
New +$235K 0.01% 375

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Ballentine Partners's KRTX Position: Q3 2023 in Review

Ballentine Partners sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q3 2023, closing a stake of 1,403 shares — an estimated $304K sold.

Ballentine Partners first reported a position in KRTX in Q3 2022 and held it in 4 quarters. The position peaked at $394K in Q1 2023. 256 funds tracked by Wall St. Rank hold KRTX as of Q3 2023.

  • Ballentine Partners reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Ballentine Partners sold 1,403 Karuna Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $304K.
  • Ballentine Partners first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2022 and held it in 4 quarters.
  • Ballentine Partners's Karuna Therapeutics, Inc. Common Stock position peaked at $394K in Q1 2023.
  • 256 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Ballentine Partners's 13F filing for Q3 2023, filed 19 Oct 2023.